ABBV vs INTC: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intel Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Intel Corporation · Technology
$68.50
-13.9% upside to fair value
High Conviction
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTC |
| Current Price |
$208.05 |
$68.50 |
| Fair Value Estimate |
$217.50 |
$59.00 |
| Upside to Fair Value |
+4.5%
|
-13.9%
|
| Market Cap |
$367.9B |
$343.9B |
| Forward P/E |
14.9x
|
-1245.8x
|
| EV / EBITDA |
16.7x
|
—
|
| Price / Sales |
6.1x
|
6.5x
|
| Price / FCF |
20.9x
|
-69.5x
|
| Revenue Growth YoY |
+8.6%
|
+0.2%
|
| Gross Margin |
83.7%
|
34.8%
|
| Operating Margin |
34.7%
|
-4.2%
|
| Return on Equity |
-129.24%
|
-0.3%
|
| Dividend Yield |
3.2% |
— |
| FCF Yield |
4.78%
|
—
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Intel is a legacy semiconductor leader attempting an ambitious turnaround under new CEO Lip-Bu Tan, pivoting from a pure-play chipmaker to an integrated device manufacturer (IDM 2.0) with foundry ambitions. The business remains structurally challenged: PC market share is eroding, foundry execution is unproven, negative free cash flow persists, and margins are compressed. However, the stock trades…
Accumulation Zones
| Metric |
ABBV |
INTC |
| Zone Low |
$163.13 |
$44.00 |
| Zone High |
$184.88 |
$50.00 |
| In Buy Zone? |
No
|
No
|